Harnessing Insights of Hepatocyte Growth Factor Kringle 3 Domain to Develop c-Met Targeted Positron Emission Tomography Probe
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.5c02886 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Renli Luo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular Medicine, College of Life and Health Sciences, Northeastern University, Shenyang 110167, China. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-met, Positron-Emission Tomography, Hepatocyte Growth Factor, Radiopharmaceuticals. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Natural Science Foundation of Shanghai Municipality, Postdoctoral Science Foundation of Shanghai Municipality, State Key Laboratory of Drug Research, Chinese Academy of Sciences.
Abstract (Originalsprache)
The cellular mesenchymal-epithelial transition factor (c-Met) is overexpressed in multiple solid tumors and is normally driven by its native ligand, hepatocyte growth factor (HGF). Despite extensive structural studies, no diagnostic agents have been developed based on the individual HGF-Kringle 3 (K3) domain. Here, four HGF-K3-derived c-Met-targeted peptide radioligands were designed for positron emission tomography (PET) imaging. Among them, [68Ga]Ga-SMIC-1014 exhibited the most favorable pharmacokinetics and achieved different tumor uptake in HCT-116, HepG2, and LNCaP xenografts. Moreover, the specific tumor targeting ability of [68Ga]Ga-SMIC-1014 was demonstrated by coinjection with an 800-fold SMIC-1014 peptide or preinjection of an excess of 25-fold onartuzumab as blocking agents, showing significant tumor signal reduction. In conclusion, the strategy of using the interface residues has been successfully explored for the discovery of new c-Met binders. [68Ga]Ga-SMIC-1014 shows a high tumor imaging performance and potential as a c-Met-targeted diagnostic probe.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Molecular Medicine, College of Life and Health Sciences, Northeastern University, Shenyang 110167, China.
- State Key Laboratory of Drug Research, Molecular Imaging Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
- School of Pharmacy, Henan University, Kaifeng 475004, China.
- School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 201203, China.
- School of Biomedical Engineering, ShanghaiTech University, Shanghai 201210. China.
- Department of Nuclear Medicine, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200235, China.
ORCID-Profile: Renli Luo, Rui Cao, Zhen Cheng
Förderung
- Natural Science Foundation of Shanghai Municipality
- Postdoctoral Science Foundation of Shanghai Municipality
- State Key Laboratory of Drug Research, Chinese Academy of Sciences
- China Postdoctoral Science Foundation
- Science and Technology Commission of Shanghai Municipality
- Science and Technology Department of Gansu Province
- National Natural Science Foundation of China
- Ningbo Major Research and Development Plan Project
Zitieren
APA
Luo, R., Sun, L., Zhao, X., Li, Y., Tan, B., Wang, T., Guo, Q., Zhang, Y., Cao, R., Qu, C., & Cheng, Z. (2025). Harnessing Insights of Hepatocyte Growth Factor Kringle 3 Domain to Develop c-Met Targeted Positron Emission Tomography Probe. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c02886
Vancouver
Luo R, Sun L, Zhao X, Li Y, Tan B, Wang T, et al. Harnessing Insights of Hepatocyte Growth Factor Kringle 3 Domain to Develop c-Met Targeted Positron Emission Tomography Probe. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c02886
BibTeX
@article{Luo2025,
author = {Luo, Renli and Sun, Luming and Zhao, Xuanyan and Li, Yonghao and Tan, Boyu and Wang, Tao and Guo, Qi and Zhang, Ying and Cao, Rui and Qu, Chunrong and Cheng, Zhen},
title = {Harnessing Insights of Hepatocyte Growth Factor Kringle 3 Domain to Develop c-Met Targeted Positron Emission Tomography Probe},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.5c02886}
}
EUVIMED